Gilead agrees to pay $247M to settle HIV drug case that alleged competition blocking
11 Aug 2023
Patent InfringementClinical Study
Details of a proposed HIV settlement with Gilead are now public, but its fate hinges on a federal judge’s OK next month.
KPH Healthcare Services, a plaintiff in a years-long antitrust case centered around Gilead and access to HIV medicines, filed a proposed order in US District Court for the District of Northern California on Wednesday. In the proposed order and filing, the settlement would require Gilead to pay $246.8 million into a settlement fund.
Preview
Source: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Indications
-Targets
-Drugs
-Chat with Hiro
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.